Gland Pharma's 0.2 U/mL RTU vials, bioequivalent to VASOSTRICT, treat shock; $45 M U.S. sales in 2025.

• Product approved for 0.2 U/mL RTU vials, matching the reference drug's efficacy and safety in critical care.
• Indicated for adults with vasodilatory shock unresponsive to fluids and catecholamines, raising blood pressure effectively.
• Gland Pharma operates in 60 countries, offering diverse injectables including oncology, ophthalmic, and heparin technologies.